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Abstract
Pancreatic cancer is a devastating human malignancy and gain of functional mutations in K-ras oncogene is observed in
75%–90% of the patients. Studies have shown that oncogenic ras is not only able to promote cell growth or survival, but
also apoptosis, depending upon circumstances. Using pancreatic cancer cell lines with or without expressing mutated K-ras,
we demonstrated that the inhibition of endogenous PKC activity sensitized human pancreatic cancer cells (MIA and PANC-1)
expressing mutated K-ras to apoptosis, which had no apoptotic effect on BxPC-3 pancreatic cancer cells that contain
a normal Ras as well as human lung epithelial BAES-2B cells. In this apoptotic process, the level of ROS was increased and
PUMA was upregulated in a p73-dependent fashion in MIA and PANC-1 cells. Subsequently, caspase-3 was cleaved. A full
induction of apoptosis required the activation of both ROS- and p73-mediated pathways. The data suggest that PKC is
a crucial factor that copes with aberrant K-ras to maintain the homeostasis of the pancreatic cancer cells harboring mutated
K-ras. However, the suppression or loss of PKC disrupts the balance and initiates an apoptotic crisis, in which ROS and p73
appear the potential, key targets.
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Introduction
Pancreatic cancer is a disease with a dismal outlook. In the
United States, approximately 33,000 patients are diagnosed with
pancreatic cancer each year and almost an equal number will die
from this malignant disease [1–3]. Worldwide, pancreatic cancer
causes a significant numbers of deaths annually. Several features of
this devastating disease are responsible for the high rate of
mortality, due to the difficulty to detect precursor lesions or
noticing the symptoms until in the advanced stages. The cancer
often undergoes micro-metastasis, which is responsible for a poor
prognosis of this disease. In addition, advanced pancreatic cancer
is often resistant to conventional chemotherapy or radiotherapy.
All of these indicate the urgency for developing new strategies to
treat this fatal disease.
Genetic, epigenetic and environmental factors are involved in
the genesis and development of pancreatic cancer [1]. The
pathogenesis of this disease is through accumulation of genetic
and molecular changes, resulting in defects in the growth,
adhesion and integration of the pancreases. The molecular
alterations in this human malignancy have been shown to
include changes in growth-related molecules, tumor suppressors
and cell cycle regulators [4–7]. Disturbances in intracellular,
mitogenic signaling pathways or proliferation restrictions provide
an advantage to tumor cells for their growth or survival.
Epidermal growth factor receptor (EGFR) family is the plasma
membrane glycoprotein and was shown to play a crucial role in
pancreatic cancer initiation and development [8–10]. The
members of EGFR have been reported to be often overexpressed
in pancreatic cancer cells, which accordantly activated its
downstream signaling pathways, such as Ras and ERK, to
promote cell growth and survival [11].
Although a variety of genetic aberrant markers have been
identified in human pancreatic cancer lesions, the most frequent
mutations were identified in K-ras, and the closely following events
were the inactivation of the tumor suppressors of p16, ARF, p53
and SMAD4 [12–14]. K-Ras belongs to the Ras family proteins
that are small cytoplasmic GTP binding proteins [15]. The
constitutively active Ras associates with GTP, and confers
uncontrollable, mitogenic-stimulatory signaling to downstream
effectors, including Raf/MAPK, PI3K/Akt, JNK/p38 and
RalGDS. A mouse model of pancreatic cancer showed that
conditional expression of an oncogenic allele of K-ras was able to
form pre-ductal lesions that progressed to invasive and metastatic
cancer at a low frequency. Concurrent knockout of p14 and ARF
promoted and transformed these pre-lesions to highly invasive and
metastatic cancers [12–14]. These results indicate that K-Ras
activation induces pre-pancreatic lesions and the tumor suppres-
sors (such as p14 or ARF) function to restrict the malignant
conversion of these precursors [12–14]. However, it has not been
fully explored if these intracellular pathways in pancreatic cancer
cells can be re-directed to switch on cell death program.
It is well known that Ras can promote not only cell proliferation
or differentiation, but also programmed cell death. In APO1-
mediated apoptosis, the ligation with APO1 (apoptosis antigen 1)
receptor caused the accumulation of membrane lipids and
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induction of apoptosis [16,17]. In lymphocytes, Ras played an
important role in IL-2- mediated apoptosis, which ensured
effective turnover of lymphocytes [18,19]. Abrupt activation of
Ras downstream effector MAP kinase pathway promoted cells to
undergo apoptosis [20,21]. In response to stress-related stimula-
tion, JNK appeared to function at downstream of Ras and induce
apoptosis in cells when stress was persistent [22]. We reported that
oncogenic Ha-Ras sensitized human or murine cells to apoptosis
when endogenous PKC activity is suppressed [22]. In this
apoptotic process, the level of ROS was increased and caspase
cascade was triggered [22]. Our present study aimed at further
testing whether K-ras mutation was synthetically lethal with loss of
PKC in pancreatic cancer cells.
PKC (protein kinase C) family consists of more than 11 isoforms
that are classified on the basis of their biochemical functions and
structures into the classical (cPKCs: a, b and c that are phorbol
ester and calcium-dependent), novel (nPKCs: d, e, g and h that
are phobol ester-dependent only) and atypical PKCs (aPKCs: f
and l that are independent of phorbol ester and calcium).
Mitogenic stimuli (such as growth factors), through increasing the
membrane DAG (diacylglycerol), activate PKC. While studies
have shown that PKC was involved in phorbol ester-mediated
mitogenic responses, it is now clear that PKC activation could
inhibit cell growth or even trigger apoptosis, depending upon types
of the isoforms, differential coupling to effectors [23,24]. For
example, PKC a often mediates proliferative or tumorigenic
responses. In intestinal or mammary cells, the same isoforms of
PKC participate in anti-proliferative responses. However, different
PKC isoforms in the same type of cells could function oppositely.
In murine NIH3T3, rat R6 or normal human colonic epithelial
cells, overexpression of PKC d caused growth arrest while
increasing level of PKC e initiated transformation process [25–
27]. Emerging evidence strongly suggested that PKC d often acts
as a tumor suppressor [24,28]. Studies showed that PKC d not
only was a negative regulator of the cell cycle progression or
positive mediator of apoptosis, but also rendered a high resistance
to skin tumor promotion induced by DMBA-phorbol ester in
animal models [29,30].
The crosstalk between PKCs and Ras signaling pathways has
been observed [31]. In different types of cells, PKC and Ras
interact either in a hierarchic linear or cooperative parallel
relationship. In response to mitogenic stimulation, PKC was
phosphorylated at various serine residues and subsequently
associated with the SH2 domain of Grb-2. The complex including
Grb-2/Sos was, in turn, formed to activate Ras signaling in T
lymphocytes [32]. The activation of PKC and Ras in lymphocytes
was then able to mobilize PI3 kinase to generate PIP3 and further
cause various protein kinase cascades, leading to the activation of
AKT and Rac to promote cell growth-related activities. It was also
reported that through affecting Rel activity, PKC had a negative
influence on Ras-mediated signaling [31]. In certain malignant
cells, PKC was activated and able to mediated Bcl-2 phosphor-
ylation for survival promotion [33,34]. By blocking pro-apoptotic
signaling pathways, PKC-induced activation of Bcl-2 was
suggested to play a significant role in lung tumorigenesis.
Inhibition of PKC by pharmacological inhibitors in cultured
human lung cancerous cells triggered an apoptotic response [35].
Our current study demonstrated that Ras preferentially induced
apoptosis in pancreatic cancer cells harboring an active K-ras after
the blockade of PKC. Our data suggested that the cooperation of
PKC appeared crucial for pancreatic cancer cells harboring
mutated K-Ras to survive.
Results
Sensitization of Pancreatic Cancer Cells Harboring
Mutated K-ras to Apoptosis after the Treatment with
GO6976
The duel functions of Ras to promote cell growth and apoptosis
was well documented [20,22]. Previously, we demonstrated that
the co-inhibition of PKC a and b expression or activity was lethal
to murine cells overexpressing v-ras [22,28]. Since K-ras mutations
are detected in most of pancreatic adenocarcinoma lesions [1], it
led us to examine the susceptibility of pancreatic cancer cells to
apoptosis in response to the treatment with GO6976 (a PKC
inhibitor specific for PKC a and b). The expression and activation
status of K-Ras in different human pancreatic cancer cell lines and
human lung epithelial cells were tested. The level of Ras
expression in human pancreatic cancer MIA or PANC-1 cells
was comparable with that in lung epithelial BEAS-2A cells and
a slightly reduced amount of Ras was detected in pancreatic
cancer BxPC-3 cells (Fig. 1A). Subsequently, the lysates from
these cells were precipitated with a RBD (Ras binding domain of
Raf)-GST fusion protein to test the activation status of Ras. An
activated Ras was co-precipitated with the fusion protein in MIA
and PANC-1 cells, but not in BxPC-3 or BEAS-2B cells (Fig. 1B).
The magnitude of Ras activation in MIA was higher than that in
PANC-1 cells.
Next, we examined the expression of PKC in these cells as well
as their responses to PKC activator PMA (phorbol myristate
acetate) or inhibitor GO6976. A comparable expression level of
PKC was detected in all the cell lines (Fig. 2A). The induction
PKC activity by PMA and inhibitory effect of GO6976 on PMA-
induced PKC activity were also examined using a PKC kinase
Figure 1. Activation status of Ras in pancreatic cancer cells. A.
The expression of Ras was examined by immunoblotting analysis in
human pancreatic cancer BxPC-3, MIA, PANC-1 or lung epithelial BEAS-
2B cells. The folds of the expression levels of Ras in pancreatic cancer
cells relative to that in BEAS-2B cells were measured and indicated.
Equal loading of total proteins per lane was determined by b-actin. B.
Ras GTP-binding activity was measure in these cells by Ras-GTP assay.
The blot was re-probed by anti-Ras antibody to judge evenly loading of
total proteins.
doi:10.1371/journal.pone.0040435.g001
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activity was slightly higher than that in untreated BxPC-3 or
BEAS-2B cells. The treatment with PMA dramatically increased
the activity of this kinase in all cell lines, which was inhibited by
GO6976, indicating that PKC was functional in all cells tested.
PKC and Ras are the crucial intracellular signal transducers
and participate in transmitting signals to regulate various
biological or patho-biological activities. The induction of
apoptosis by PKC suppression was reported in murine or human
cells expressing oncogenic ras [20,22,28]. To test whether
GO6976 was able to induce apoptosis in pancreatic cancer cell
lines with or without expressing mutated K-ras, annexin V assay
was performed (Fig. 3A and B). GO6976 treatment dramati-
cally sensitized MIA and PANC-1 cells to apoptosis and played
no role in the induction of apoptosis in BxPC-3 cells that contain
normal Ras signaling as well as in human lung epithelial BEAS-
2B cells. Notably, MIA cells in which Ras activity was higher
were more susceptible to GO6976-induced apoptosis than
PANC-1 cells. To determine if Ras was responsible for the
induction of apoptosis, farnesyltransferase inhibitor (FTI) to
suppress Ras activity was used (Fig. 3C). In the presence of FTI,
GO6976 treatment was unable to induce apoptosis in MIA or
PANC-1 cells. The data suggested that mutated K-Ras, together
with loss of PKC function, appeared lethal and this lethal
reaction might be regulated by mutated Ras.
Upregulation of ROS by GO6976 in Pancreatic Cancer
Cells Harboring Mutated K-ras for the Induction of
Apoptosis
ROS (reactive oxygen species) is known to be required for cell
growth and on the contrary, a persistently increased in ROS was
shown to be able to cause DNA damage or trigger apoptosis [36].
Studies revealed that ROS in cells expressing oncogenes (such as
ras) were often augmented, which might be due to high metabolic
needs of neoplastic growth [36]. ROS levels in pancreatic cancer
and BEAS-2B cells were measured under normal growth
conditions or after the treatment with GO6976 (Fig. 4A). A
moderate amount of ROS was detected in MIA or PANC cells,
which was dramatically elevated after the addition of GO6976.
ROS was at baseline levels in untreated BxPC-3 or BEAS-2B cells
and the treatment with the PKC inhibitor did not affect ROS
production or accumulation.
To determine whether ROS played a role in the induction of
apoptosis following PKC inhibition in pancreatic cancer cells
expressing mutated K-ras, annexin V assay was conducted
(Fig. 4B). Again, MIA and PANC-1 cells were sensitive to
GO6976 treatment, which was partially, but significantly blocked
by NAC (N-acetyl-L-cysteine, a ROS inhibitor). Since NAC did
not completely suppressed apoptosis in these cells, it suggested the
participation of other pathways in the execution of this cell death
program. Consistently, pancreatic cancer cells without expressing
Figure 2. PKC expression and activity following PMA or PMA plus GO6976 treatment. A. Cell lysates isolated from untreated cells were
immunoblotted with anti-pan-PKC antibody. b-actin was used to determine equal loading of total protein per lane. B. Cell lysates from the cells with
or without being treated with PMA or PMA plus GO6976, were immunoprecipitated with anti-pan-PKC antibody. The immunocomplexes were
incubated with [
32P] c-ATP and the peptide substrates to analyze PKC activity. The error bars represented SD from three independent experiments
(n=3, r,0.05).
doi:10.1371/journal.pone.0040435.g002
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responsive to GO6976 as well as to the combination treatment of
GO6976 plus NAC.
Activation of Caspase 3 in this Lethal Reaction Occurred
in MIA or PANC-1 Cells
Caspase family consists of more than 10 members [37]. In
response to apoptotic stimuli, caspase-3 was shown to function as
an executioner in caspase cascade for the completion of cell death
program [37]. In this process, caspase-3 was required to be cleaved
into a small, active fragment. To test the activation status of
caspase 3, the presence of the cleaved caspase 3 in MIA or PANC-
1 cells was analyzed by immunoblotting (Fig. 5A). Following the
treatment with GO6976, a small, cleaved caspase-3 was indeed
present in these two pancreatic cancer cells. The active form of this
caspase was undetectable in GO6976-treated BxPC-3 or BEAS-2B
cells (data not shown). To further examine the activation of
caspase 3 under the same experimental setting, caspase 3 activity
was analyzed (Fig. 5B). Following the treatment with the
inhibitor, the activity of this protease was upregulated in MIA
and PANC-1 cells, which was partially suppressed by adding
NAC. Consistently, the activity of caspase 3 was absent in
GO6976-treated BxPC-3 cells without expressing mutated K-ras or
BEAS-2B cells. The results suggested that caspase 3 participated in
the execution of the GO6976-induced apoptosis in pancreatic
cancer cells harboring oncogenic K-ras.
Upregulation of the Apoptotic Factor PUMA in a p73-
dependent Fashion During GO6976-Induced Apoptosis
p73 belongs to p53 family and shares homology with p53 not
only in their sequences, but also the transactivation, DNA-
binding or oligomerization functions [38]. In the p73-mediated
apoptosis, the apoptotic-related factor PUMA was often
upregulated [38]. We previously reported that after PKC
inhibition, p73 in murine fibroblasts ectopically expressing Ha-
ras was activated and responsible for the initiation of apoptosis
[28]. During this cell death process, p73 was phosphorylated at
its serine residues [28]. To test whether p73 was phosphorylated
in GO6976-treated MIA or PANC-1 cells, immunoblot analysis
was conducted (Fig. 6A). The phosphorylation of p73 was
occurred at its serine residues in the treated cells, but not in
control cells. The GO6976-mediated p73 phosphorylation did
not altered by the addition of NAC. Subsequently, the
expression of p73-regulated PUMA gene in MIA or PANC-1
Figure 3. Induction of apoptosis in GO6976-treated pancreatic cancer cells. A. Cells were treated with GO6976 (1 mM) for 48 h and then
collected for annexin V assay. The error bars are SD from 5 independent experiments (n=5, r,0.05). B. Profiles of the cells after being stained with
annexin V. C. Cells were treated with FTI for 30 min prior to GO6976 treatment. Subsequently, annexin V assay was conducted. The error bars are SD
from 5 independent experiments (n=5, r,0.05).
doi:10.1371/journal.pone.0040435.g003
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level of the gene expression in the cells was significantly
increased after the treatment with GO6976. The upregulation
of the gene was again unchanged in the presence of NAC, but
completely suppressed by the transient infection of shRNA-p73.
Consistently, the protein expression was augmented after the
treatment with the PKC inhibitor (Fig. 6B). The introduction
of shRNA-p73 into the cells also blocked the induction of PUMA
protein, which was not affected by the addition of NAC (data
not shown). It appeared that PUMA was involved in the axis of
p73-mediated signaling in this apoptotic process.
Cooperation of ROS and p73 for the Induction of
GO6976-mediated Apoptosis
It is well known that multiple, apoptotic signaling pathways are
being integrated for a full execution of cell death program. Since
ROS and p73 appeared taking part in the induction of apoptosis in
GO6976-treated pancreatic cancer cells harboring mutated K-ras,
Figure 4. Upregulation of ROS and induction of apoptosis in pancreatic cancer cells. A. The cells were treated with GO6976 or co-treated
with GO6976 plus NAC (2.5 mM). After being stained with DCF, the levels of ROS in the cells were analyzed by a flow cytometer. B. The cells were
treated with GO6976 (1 mM) or GO6976 plus NAC. Subsequently, the samples were collected and subjected for annexin V assay. The error bars are SD
from 5 independent experiments (n=5, r,0.05).
doi:10.1371/journal.pone.0040435.g004
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the pancreatic cancer cells (Fig. 7A). Again, a moderate among of
ROS was detected in untreated MIA or PANC-1 cells, which was
further increased after PKC inhibition. The transient infection of
shRNA-p73 had no influence on the induction of ROS, suggesting
that p73 in our experimental setting was not involved in the ROS
signaling. Subsequently, caspase-3 activity was analyzed after the
knockdown of p73 or co-inhibition of p73 and ROS (Fig. 7B). The
introduction of shRNA-p73 partially blocked the activity of caspase-
3 in GO-6976-treated MIA or PANC-1 and the activity of this
protease was completely abolished after the co-suppression of p73
and ROS. The occurrence of apoptosis after the same treatments
was then analyzed by annexin V assay (Fig. 7C). The knockdown
of p73 partially inhibited the GO6976-induced apoptotic process in
MIA or PANC-1 cells. In the absence of both p73 and ROS,
GO6976 was unable to initiate apoptosis in these cells. The data
Figure 5. Caspase 3 activation in response to the suppression of PKC. A. With or without GO6976 treatment, cell lysates were prepared and
immunoblotted with anti-caspase 3 antibody. B. The cells were subjected to the treatment with GO6976 or GO6976 plus NAC. Subsequently, annexin
V assay was performed. The error bars represent SD from 3 independent experiments (n=3, r,0.05).
doi:10.1371/journal.pone.0040435.g005
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part in this lethal reaction.
Discussion
Pancreatic cancer is a devastating human malignancy and one
of the leading causes of cancer death [1]. Prognosis of this disease
is dismal, because of the lack of effective treatments. It is known
that gain of functional mutations in K-ras occur at early stages in
human pancreatic cancer patients or mouse models that were
generated by knockout of tumor suppressor genes of p16, Arf,o r
p53, respectively or in combinations [12–14]. These findings
indicate the importance of K-Ras in the genesis and development
of pancreatic cancer. The goal of our study was to explore the new
strategy targeting oncogenic Ras for pancreatic therapeutics. The
present study demonstrated that aberrant, mutated K-ras was able
to re-direct pancreatic cancer cells towards to apoptosis following
the suppression of PKC. In this apoptotic process, multiple
signaling pathways were involved. After the treatment with the
PKC inhibitor, the level of ROS in the pancreatic cancer cells
expressing mutated K-ras was increased, accompanied with the
induction of apoptosis. However, the addition of NAC partially
blocked the cell death process. p73 was phosphorylated and,
PUMA gene and protein were upregulated. Furthermore, caspase
3 was cleaved for the execution of cell death program. The co-
inhibition of ROS and p73 achieved an ultimate blockade effect
on apoptosis in GO6976-treated pancreatic cancer cells harboring
mutated K-ras. Thus, our study indicates that aberrant Ras,
together with loss of PKC is synthetically lethal in the pancreatic
cancer cells. The data also suggested a potential balance between
Ras and PKC that determines the threshold of apoptosis in the
cells.
Figure 6. Phosphorylation of p73 and upregulation of PUMA in pancreatic cancer cells. A. With or without the treatment with GO6976 or
GO6976 plus NAC, lysates were immunoprecipitated with anti-p73 antibody. The immunoprecipitates were then subjected to immunoblotting using
the anti-phosphorylated serine antibody. The level of the immunoprecipitates was judged by re-probing the blot with anti-p73 antibody. B. Total
RNAs from the cells with or without treated with GO6976, GO6976 plus NAC or GO6976 plus shRNA-p73 infection were isolated. Equal amount of
RNAs was reverse-transcribed, and the expression of PUMA was tested by RT-PCR. C. With or without GO6976 treatment, MIA or PNAC-1 cells were
subjected to immunoblotting analysis for PUMA expression. Equal loading of total proteins were determined by rep-probing the blot with anti-b-
actin antibody.
doi:10.1371/journal.pone.0040435.g006
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during the initiation and development of various types of human
malignancies [15]. In the process of transformation, persistent
increases in Ras activity switch on various downstream effector
pathways, leading to phosphorylation chain reactions for the
activation of pro-growth transcriptional factors [39]. Despite the
essential involvement in cell growth and differentiation, hyperac-
tive Ras, under certain circumstances, can be re-directed to
apoptosis. Numerous studies have highlighted the roles of Ras in
the regulation of apoptosis [20]. In particular, it has been observed
that treatments with PKC inhibitors could induce apoptosis in
murine fibroblasts or rat lung epithelial cells overexpressing
oncogenic ras [22,28]. Here, we demonstrate that PKC activity in
the pancreatic cancer cells harboring mutated K-ras was slightly
augmented, which might be necessary for coping with aberrantly
high Ras activity for surviving. After PKC was suppressed,
mutated K-Ras could not maintain high metabolic needs of the
cancer cells and the lethal reaction was initiated. Since high
percentages of human cancers harboring oncogenic ras, PKC
appears an ideal intracellular target for the induction of apoptosis,
with a low or none toxic effect on surrounding normal tissues or
cells.
More than 11 serine/threonine protein kinases belong to PKC
family, some of which are structurally distinct or functionally
diverse. However, there is a functional redundancy among these
PKC isozymes for restoring normal physiological status when one
or more PKC isozymes are knocked out or nonfunctional. The
roles of PKC isoforms in the regulation of cell growth or death are
rather controversial, depending upon different types of cells or
cellular contexts. For example, it has been suggested that PKC a,
b, d possessed duel roles in the regulation of cancer development
or programmed cell death, indicating the complexity of these PKC
isozymes [24]. Cross-talks among PKC isoforms and with other
intracellular signal transducers were often present in a hierarchy
order or different compartments to guide cells to achieve different
outcomes. It was also shown that PKC and Ras signaling pathways
were interconnected, especially in lymphocytes [24,40]. Upon
mitogenic stimulation, the SH2 binding sites of PKC were
phosphorylated, which in turn recruits the Grb2/SOS complex
and further activated Ras signaling in T lymphocytes [24]. PKC
was reported to negatively regulated Ras pathway, through
affecting its effector Rel [24]. In NIH3T3 cells ectopically
expressing v-Ha-ras, p73 functioned downstream of PKCa and
b and as a sensor to determine the threshold of apoptosis [22].
Using the PKC inhibitor GO6976 that inhibits the phorbol ester-
dependent PKC isoforms, we in this study showed that the
pancreatic cancer cells with hyperactive K-Ras could be efficiently
sensitized to apoptosis. The investigation to identify key PKC
isoform(s) in the regulation of this apoptotic process is under way.
Figure 7. Induction of apoptosis in pancreatic cancer cells harboring mutated K-ras.A .The level of ROS in the cells treated with GO6976 or
GO6976 plus shRNA-p73 infection was analyzed. The error bars represent SD from 3 independent experiments (n=3, r,0.05). B. The activity of
caspase 3 in the cells treated with GO6976, GO6976 plus shRNA-p73 infection or GO6976 plus NAC plus shRNA-p73 infection was assayed. The error
bars represent SD from 3 independent experiments (n=3, r,0.05). C. Annexin V assay in MIA and PANC-1 cells treated with GO6976, GO6976 plus
shRNA-p73 infection or GO6976 plus NAC plus shRNA-p73 infection was performed. The error bars represent SD from 3 independent experiments
(n=3, r,0.05).
doi:10.1371/journal.pone.0040435.g007
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factors [36]. Some mitogenic stimuli are able to augment the level
of intracellular ROS, resulting in altering the structure of the
cytoskeleton and further inducing transformation [36]. In PC12
cells, Ras was shown to upregulate ROS production upon EGF
stimulation [41]. Studies also demonstrated that oncogenes (such
as myc or ras), through persistently perturbing the state of
intracellular redox, were able to cause chromosomal aberrations
and subsequently disrupt genetic integrity to promote tumorigen-
esis [36]. Despite regulating cell proliferation and transformation,
an increase in ROS was suggested to play an obligatory role in the
induction of apoptosis [22]. In TNFa-induced programmed cell
death, NF-kB and JNK cooperated to stimulate ROS production,
leading to caspase cascade and mitochondrial depolarization [42].
Ectopic expression of Ha-ras in murine fibroblasts induced cell
death through eliciting ER (endoplasmic reticulum) stress and
activating UPR (unfolded protein response) [22]. The current
study demonstrated that although ROS was moderately elevated
in pancreatic cancer cells expressing mutated K-ras under normal
growth conditions, inhibition of PKC severely disrupted the
equilibrium of the redox state and induced a significant accumu-
lation of ROS in the cells. Thus, PKC appears an important factor
to maintain the homeostasis of pancreatic cancer cells harboring
an aberrant K-ras.
p73 belongs to p53 family proteins and, shares the structural
and functional homologue with p53 [38]. Studies showed that p73
played a significant role in DNA damage- or stress-induced
apoptosis. Nuclear c-Abl was activated by genotoxic stress and
further phosphorylated p73 for the induction of apoptosis [43]. In
this cell death process, nuclear c-Abl interacted with p73 and
further stimulated p73-regulated activities. It was also shown that
in response to ionizing radiation or cisplatin treatment, p73 played
a key role in the transmission of the apoptotic signaling [44]. In
murine fibroblasts overexpressing v-Ha-ras, PKC d interacted with
and further activated p73 to trigger an apoptotic crisis [28]. In this
study, we demonstrated that p73 was phosphorylated in pancreatic
cancer cells harboring mutated K-ras, and subsequently upregu-
lated the level of the expression of the apoptotic factor PUMA.
The underlying mechanism by which PUMA participates in this
apoptotic process remains to be further investigated.
In summary, genetic mutations in K-ras appear uniquely present
in90%of human pancreaticcancer lesionsand this disease is one of
the leading causes ofcancer death. Thus,there is anurgent needfor
discoveries of effective treatments clinically. Our current study
demonstratedthataberrantK-Rascouldre-directpancreaticcancer
cells towards apoptosis, in which ROS and p73 appeared necessary
for the initiation of this cell death program. Under normal growth
conditions, gain or loss of function of either Ras or PKC alone is
compatible with the viability of cells. However, when PKC activity
or expression is suppressed, hyperactive K-Ras is unable to sustain
the homeostasis, resulting in an apoptotic crisis. The data presented
here provide a foundation for developing new therapeutic strategies
that can kill pancreatic tumors harboring mutated K-ras at clinically
achievable doses, with effective indices that are better than those of
existing drugs.
Materials and Methods
Cells and Antibodies
Human pancreatic cancer BxPC-3, MIA, and PANC-1 cells
were purchased from ATCC (American Type Culture Collection,
Rockville, MD) and cultured in Dulbecco modified Eagle medium
(DMEM) containing 10% newborn calf serum (Gibco, Gaithers-
burg, MD). Human lung epithelial cells were also purchased from
ATCC and cultured in the medium according to the recommen-
dation by the company. The shRNA-p73 inserted in a lentiviral
small-hairpin RNA expression vector was transiently infected into
cells.
Anti-Ras, GST, PKC, caspase-3 and phor-p73 antibodies were
purchased from Cell Signaling Technology.
Measurement of Ras Activation
After the treatments, cells were lysed in a buffer containing
25 mM HEPES, pH 7.5, 150 mM NaCl, 0.25% sodium deox-
ycholate, 10% glycerol and 25 mM NaF. Proteins were normal-
ized to 1 mg/ml, and precipitated by mixing with 20 mg of Raf-
RBD overnight at 4uC. The complexes were washed and
separated on a 10% SDS-PAGE gel and immunoblotted with an
anti-pan-Ras antibody.
Analysis of ROS
Treated or untreated cells were washed with ice-cold PBS and
resuspended in 5 mg/ml of 29,7 9-dichlorodihydrofluorescein
diacetate (DCF) (Molecular Probes). The samples were incubated
for 10 min at room temperature and analyzed immediately by
a flow cytometer.
Immunoblotting Analysis
After treatments, cells were lysed in the lysis buffer (50 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 1% Triton-X114, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulfate, containing 1 mM
phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, 1 mg/ml leu-
peptin, 1 mg/ml pepstatin A) on ice for 30 min. The total protein
concentrations in the cell lysates were normalized, separated on
a 10%SDS-PAGE gel, and visualized by corresponding antibodies.
PKC Enzymatic Assay
Following treatments, PKC activity in cell lysates was analyzed
using PKC assay kit (Cell Signaling Technology) that contains
a specific substrate peptide for PKC and an inhibitor mixture to
block other serine/threonine kinases (such as the inhibitors of PKA
and calmodulin-dependent kinases). Subsequently,
32P-incorpo-
rating substrates were separated from the residual [
32P] ATP using
p81 phosphocellulose papers and the radioactivity incorporated
into the substrates was measured by a scintillation counter.
Annexin V Assay
After treatments, cells (1 x 10
6) were washed twice with cold
PBS and stained with Annexin V-FITC using the Annexin kit (BD
Biosciences) to detect apoptotic cells using a flow cytometer or
counted 150 cells under a fluorescent microscope.
Statistical Analysis
Three to five independent repeats were conducted in all
experiments. Error bars represent these repeats. A Student’s T test
was used and a r value of ,0.05 was considered significant.
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